Structure–Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2<i>H</i>,4<i>H</i>)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Structure–Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2H,4H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer

Published:2024-08-29 Issue:17 Volume:67 Page:15837-15861
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhao Xiaobao¹,Zhong Changxin²³,Zhu Rongfeng¹,Gong Rong²³,Liu Bingyan¹,He Linhao²³,Tian Sheng¹⁴,Jin Jing¹,Jiang Ting²³,Chen Jing-Lei¹,Wan Xiaoya²³,Liu Wenjing¹,Jiang Shilong⁵,Deng Pan¹,Cheng Yan²³⁶,Ye Na¹⁴^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

2. Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China

3. Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China

4. Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China

5. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410011, China

6. Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, Changsha 410011, China

Funder

Fundamental Research Funds for Central Universities of the Central South University

Natural Science Foundation of Hunan Province

Hunan Provincial Innovation Foundation for Postgraduate

Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions

National Natural Science Foundation of China

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01484

Reference41 articles.

1. Breast Cancer: Current Perspectives on the Disease Status

2. Triple-negative breast cancer molecular subtyping and treatment progress

3. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications

4. Targeting triple-negative breast cancer: A clinical perspective

5. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer